Dapagliflozin / saxagliptin Pill
RxNorm 1925496

Concept Hierarchy & Relationship Mapping

RxNorm Concept Unique Identifier (RxCUI) 1925496 represents a standardized clinical drug concept used for cross-system interoperability. This concept aggregates multiple Atom IDs (AUIs), which are specific naming variations and synonyms used across pharmaceutical databases to ensure accurate medication mapping for: dapagliflozin / saxagliptin Pill.

The following semantic concepts and normalized strings are associated with this clinical entity:

SCDG
Dapagliflozin / saxagliptin Pill
AUI:9189898
TMSY
Dapagliflozin / sAXagliptin Pill
AUI:12430434

This clinical crossover tool is designed for healthcare professionals, pharmacists, and data analysts to safely compare substitute products and manage medication interoperability.

SCDGPrescribable

Semantic Clinical Dose Form Group (SCDG):
Dapagliflozin / saxagliptin Pill
(Atom ID: 9189898)

Clinical Status & Identity

Prescribable Status
YES (Active)
Part of the RxNorm Current Prescribable Content subset including all drugs available for prescription in the USA.
Concept Description
dapagliflozin / saxagliptin Pill
Official description of the drug concept as defined in the source vocabulary.
Suppress Flag
N
N: Not suppressible | O: Obsolete | Y: Suppressed by editor | E: Unquantified non-prescribable drug.

Interoperability & Coding

Concept ID (RxCUI)
1925496
RxNorm Unique Identifier for the standardized concept.
Atom ID (RXAUI)
9189898
Unique identifier for this specific name variation (Atom).
Term Type (TTY)
SCDG
Semantic Clinical Dose Form Group (Ingredient + Dose Form Group)
Source Code
1925496
The "Most useful" identifier asserted by the original source vocabulary.

Source & Registry Data

Source Name
RxNorm Vocabulary (RXNORM)
The official name and abbreviation for the vocabulary source.
Source Version
20AA_260601F
The specific version of the vocabulary provided by the source.
Update Date
May 04, 2026
The date when this RxNorm data was last updated by the NLM.
License Contact
RxNorm Customer Service, , U.S. National Library of Medicine, 8600 Rockville Pike, , Bethesda, MD, United States, 20894, (888) FIND-NLM, , https://support.nlm.nih.gov/support/create-case/, https://www.nlm.nih.gov/research/umls/rxnorm/
Source licensing contact information.

Technical Attributes & Logic

RXN AVAILABLE STRENGTH
10 MG / 5 MG
Available drug strengths listed in the order of ingredients from the drug
RXN AVAILABLE STRENGTH
5 MG / 5 MG
Available drug strengths listed in the order of ingredients from the drug

TMSYPrescribable

Tall Man Lettering Synonym (TMSY):
Dapagliflozin / sAXagliptin Pill
(Atom ID: 12430434)

Clinical Status & Identity

Prescribable Status
YES (Active)
Part of the RxNorm Current Prescribable Content subset including all drugs available for prescription in the USA.
Concept Description
dapagliflozin / sAXagliptin Pill
Official description of the drug concept as defined in the source vocabulary.
Suppress Flag
N
N: Not suppressible | O: Obsolete | Y: Suppressed by editor | E: Unquantified non-prescribable drug.

Interoperability & Coding

Concept ID (RxCUI)
1925496
RxNorm Unique Identifier for the standardized concept.
Atom ID (RXAUI)
12430434
Unique identifier for this specific name variation (Atom).
Term Type (TTY)
TMSY
Tall Man Lettering Synonym (Tall Man Lettering synonym of another TTY, given to distinguish between commonly confused drugs.)
Source Code
1925496
The "Most useful" identifier asserted by the original source vocabulary.

Source & Registry Data

Source Name
RxNorm Vocabulary (RXNORM)
The official name and abbreviation for the vocabulary source.
Source Version
20AA_260601F
The specific version of the vocabulary provided by the source.
Update Date
May 04, 2026
The date when this RxNorm data was last updated by the NLM.
License Contact
RxNorm Customer Service, , U.S. National Library of Medicine, 8600 Rockville Pike, , Bethesda, MD, United States, 20894, (888) FIND-NLM, , https://support.nlm.nih.gov/support/create-case/, https://www.nlm.nih.gov/research/umls/rxnorm/
Source licensing contact information.